# Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

> **NCT00376064** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide acetate and cabergoline/Octrotide and Somavert

## Key facts

- **NCT ID:** NCT00376064
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-01
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376064, "Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00376064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*